1	Comprehensive analysis of immune responses in CLL patients after heterologous
2	COVID-19 vaccination
3	
4	Running title: Immune response in vaccinated CLL patients
5	
6	Hye Kyung Lee ^{1,*} , Manuela A. Hoechstetter ^{2,*} , Maike Buchner ^{3,4,*} , Trang Thu Pham ² ,
7	Jin Won Huh ⁵ , Katharina Müller ^{6,7} , Sabine Zange ^{6,7} , Heiner von Buttlar ^{6,7} , Philipp Girl ^{6,7} ,
8	Roman Wölfel ^{6,7} , Lisa Brandmeier ³ , Lisa Pfeuffer ³ , Priscilla A. Furth ⁸ ,
9	Clemens-Martin Wendtner ^{2,#} and Lothar Hennighausen ^{1,#}
10	
11	¹ National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of
12	Health, Bethesda, MD 20892, USA.
13	² Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University
14	(LMU), Munich, Germany.
15	³ Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical
16	University of Munich, Munich, Germany.
17	⁴ TranslaTUM - Central Institute for Translational Cancer Research, Technische
18	Universität München, 81675 Munich, Germany.
19	⁵ Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University
20	of Ulsan College of Medicine, Seoul, Korea.
21	⁶ Bundeswehr Institute of Microbiology, Munich, Germany
22	⁷ German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany
23	⁸ Departments of Oncology & Medicine, Georgetown University, Washington, DC, USA.
24	
25	* co-first authors
26	# co-senior authors
27	
28	Correspondence: LH (lotharh@nih.gov) and CMW (clemens.wendtner@muenchen-
29	<u>klinik.de</u>)
30	
31	

2

32 Abstract

Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors 33 and anti-CD20 antibodies exhibit low humoral response rate (RR) following SARS-CoV-34 2 vaccination. To investigate the relationship between the initial transcriptional response 35 to vaccination with ensuing B and T cell immune responses, we performed a 36 comprehensive immune transcriptome analysis flanked by antibody and T cell assays in 37 peripheral blood prospectively collected from 15 CLL/SLL patients vaccinated with 38 heterologous BNT162b2/ChAdOx1 with follow up at a single institution. The two-dose 39 antibody RR was 40% increasing to 53% after booster. Patients on BTKi, venetoclax ± 40 anti-CD20 antibody within 12 months of vaccination responded less well than those under 41 BTKi alone. The two-dose T cell RR was 80% increasing to 93% after booster. 42 43 Transcriptome studies revealed that seven patients showed interferon-mediated signaling activation within 2 days and one at 7 days after vaccination. Increasing counts of COVID-44 45 19 specific IGHV genes correlated with B-cell reconstitution and improved humoral RR. T cell responses in CLL patients appeared after vaccination regardless of treatment 46 47 status. A higher humoral RR was associated with BTKi treatment and B-cell reconstitution. Boosting was particularly effective when intrinsic immune status was 48 49 improved by CLL-treatment.

50

51 Introduction

Patients with chronic lymphocytic leukemia (CLL) are considered high-risk for severe 52 COVID-19 infection, mainly due to their complex underlying immunodeficiency and 53 inadequate immune response to infections.¹⁻³ They not only suffer from immune 54 dysregulation by the disease itself, but their immune system is further disrupted by 55 effects.⁴⁻⁶ 56 treatment-related Patients. who are heavily pre-treated with chemoimmunotherapy, exposed to anti-CD20 antibody or treated actively with B-cell 57 pathway inhibitors, experience suboptimal antibody response to COVID-19 vaccination 58 compared to CLL treatment-naïve.7-13 Robust data on immunogenicity of 2-dose 59 homologous or heterologous BNT162b2/ChAdOx1 vaccine schedules in leukemia 60 patients have demonstrated an enhanced humoral and/or cellular immune response.^{14,15} 61 Heterologous vaccine schedules also enhance humoral response in individuals without 62

3

hematological disease.^{16,17} The European Medicines Agency (EMA) and the European
 Centre for Disease Prevention and Control (ECDC) discussed potential benefits of
 heterologous regimens in 2021.¹⁸

While CLL patients who received their last treatment within 12 months preceding 66 standard vaccination program demonstrate low response rates, vaccine response rates 67 increase in seronegative, actively treated patients following boosting.^{14,19} In addition, 68 potential protection against COVID-19 infection provided by T cells, even in the absence 69 of a humoral response, is of particular clinical interest.^{20,21} T cell activation with release 70 of IFN- γ by SARS-CoV-2 is associated with mild disease and viral clearance.^{21,22} T cell 71 mediated immune responses are reported in patients with lymphoid malignancies in the 72 absence of a humoral response.²³ However, in a mixed group of cancer patients, they 73 were documented more commonly in combination with a humoral response.²⁴ 74

Early responses to vaccination are elevated levels of interferons and other 75 cytokines, which activate the JAK/STAT signaling pathway and induce expression of 76 immediate and innate response genes. We have used RNA-seq of peripheral immune 77 cells to identify the innate immune response of healthy individuals receiving the standard 78 homologous BNT162b2²⁵ or a heterologous ChAdOx1/BNT162b2¹⁷ regimen. Specific 79 genetic pathways are differentially activated within the first two days after vaccination and 80 more prominently in the heterologous cohort. However, there are no reports in the 81 literature on the immune transcriptomic response in CLL patients receiving COVID-19 82 vaccines. 83

The utility of heterologous vaccination regimens for improving immune response in immune compromised patients continues to be deliberated.^{26,27} To add to this important discussion, here we provide a comprehensive transcriptome analysis of peripheral immune cells from CLL patients who received heterologous ChAdOx1/BNT162b2 vaccination and monitored their innate and humoral immune response until four months following third vaccination in combination with detailed discussion of disease-status, treatment regimens, and response to COVID-19 infection during follow-up.

91

92 Methods

93 Ethical approval

4

Ethical approval (#20-225) to conduct this analysis was granted by the institutional review board of the Ludwig-Maximilian University (LMU), Munich as the responsible ethics committee. Written informed consent was obtained from the study participants.

97

98 Study population, study design and recruitment

From June 2021 through July 2021, 15 patients diagnosed with CLL/SLL between 2003 99 and 2021 were recruited in a single institution (Department of Hematology and Infectious 100 Diseases, Munich Clinic, Munich Schwabing, Germany), per recommendation of booster 101 vaccination by the Standing Committee on Vaccination (STIKO) at the Robert Koch 102 Institute in Germany. After providing written informed consent for data collection, five 103 seronegative patients received a third (3-dose) after standard 2-dose homologous 104 vaccination of BNT162b2 or ChAdOx1. All were heavily pretreated (103, 104) or recently 105 treated with anti-CD20 mAbs (105, 106) or a BTK inhibitor (107). In addition, ten patients 106 107 (2-dose) with different CLL disease and treatment status (201 to 213), half of whom were seropositive after prime dose of ChAdOx1, received a second homologous or 108 109 heterologous dose. At the time of vaccination 14 of 15 patients did not have a history of COVID-19 infection. Between October 2021 and December 2021, all ten patients of 2-110 111 dose received a third BNT162b2 dose. Antibody response and incidence and outcome of COVID-19 infections were recorded per routine CLL management. Four patients had a 112 113 breakthrough COVID-19 infection with Omicron variant around six months after the third vaccination, all with mild symptoms. One patient received antiviral treatment with 114 molnupiravir. Patient #209 had an undiagnosed infection in January 2020, confirmed by 115 anti-SARS-CoV-2 nucleocapsid IgG antibodies in follow-up. 116

117

118 Stimulation of lymphocytes and detection of IFN-γ

For lymphocyte stimulation studies, heparinized blood samples were transported within four hours of collection to the laboratory. 1mL sample was then transferred to three QuantiFERON (QFN) ® SARS-CoV-2 (Qiagen) SARS-CoV-2 blood collection tubes (Sars-CoV-2 specific antigens AGI, AGII, AGIII). After 24 hours of stimulation, plasma from the stimulated samples was used for the detection Interferon gamma (IFN- γ).

5

124 Detection was carried using the QuantiFERON \circledast ELISA Human IFN- γ (Qiagen). Detected 125 IFN- γ level >0.1 IU/ml is evaluated as positive response.

126

127 SARS-CoV-2 antibody ELISA

End-point binding IgG levels to the S1 domain of the spike protein of SARS-CoV-2 were measured using the semi-quantitative Anti-SARS-CoV-2 ELISA IgG (EUROIMMUN, Lübeck), according to the manufacturer's instructions. Positive responses included both IgG ratio \geq 1.1 and borderline values IgG \geq 0.8 to <1.0. Negative responses were IgG ratio < 0.8. In addition, Quantitative Anti-SARS-CoV-2 ELISA IgG measurement (Atellica IM SARS-CoV-2 IgG, Siemens) was performed with positive response >= 21.8 Binding Antibody Unit/ml (BAU/ml) and negative < 21.8 BAU/ml.

135

136 Virus Neutralization Test

SARS-CoV-2 (strain MUC IMB-1, clade B1) neutralizing antibody titers were determined 137 as previously described²⁸, including positive and negative controls. Heat-inactivated 138 139 serum samples in duplicates, including positive and negative control samples, were serially diluted in 96-well tissue culture plates starting at 1:5 to a maximum of 1:640. Virus 140 141 stocks (50 TCID/50 µl) were prepared and stored at -80 °C until further use. Virus was pre-incubated (1 h, 37 °C) with diluted serum samples before Vero E6 cells (1×10⁴ cells/50 142 143 µI) were added. After 72 h (37 °C), supernatants were discarded and wells were fixed (13% formalin/PBS) and stained (crystal violet, 0.1%). The neutralizing antibody titer 144 corresponded to the reciprocal of the highest serum dilution showing complete inhibition 145 cytopathic effect (CPE). 146

147

148 Flow Cytometry

Cells were stained with fluorochrome-labeled antibodies to manufacturer information
(Staining 1: CD19 PE-Cy7 and CD5 APC; Staining 2: CD3 FITC, CD4 APC-Cy7, CD8
Amcyan, PD1 PE-Cy7, CD25 PE, CD62L APC; staining 3: CD11c PE, CD14 APC-Cy7,
HLA-DR PE-Cy7, CD56 PerCP710, all Biolegend). To block free Fc receptors human Fc
Receptor Binding Inhibitor Polyclonal Antibody (eBioscience) were added 10 min prior to
labeled antibodies. Dead cells were excluded by DAPI (1 µg/ml) (Sigma Aldrich) staining.

6

Flow cytometric analysis was performed using a FACS Canto II cytometer (BD
Bioscience). Data was analyzed with the FlowJo[™] software version 10.7.1 (BD
Bioscience).

158

159 Extraction of the buffy coat and purification of RNA

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density 160 gradient centrifugation using Ficoll-Pague (GE Healthcare, Chicago, IL, USA). CD19⁺B-161 cells were depleted by magnetic-activated cell sorting (MACS) using human CD19 162 MicroBeads (Miltenyi, Bergisch-Gladbach, Germany) if CLL cell population exceeded 163 10% of viable lymphocytes, as determined by flow cytometry, prior to RNA extraction. 164 3x10e6 PBMC (with or without CD19 depletion) were collected, washed with PBS and 165 166 resuspended in 200ul Homo-TG buffer (Maxwell® 16 LEV simplyRNA Purification Kit, Promega) and stored at -80°C. RNA was extracted on the Maxwell® 16 Instrument 167 according to manufacturer's protocol and stored at -80°C for further processing. 168

169

170 mRNA sequencing (mRNA-seq) and data analysis

Bulk RNA-seq was performed on three million PBMCs obtained prior to the second 171 172 vaccination (2-dose cohort) and third vaccination (3-dose cohort) and at days 1/2 (D1/2), 7 (D7) and week 4-5 (W4-5) after the vaccination. RNA-seq was conducted on a total of 173 XX samples with an average sequencing depth of at least 200 million reads per sample. 174 The Poly-A containing mRNA was purified by poly-T oligo hybridization from 1 mg of total 175 RNA and cDNA was synthesized using SuperScript III (Invitrogen). Libraries for 176 sequencing were prepared according to the manufacturer's instructions with TruSeg 177 Stranded mRNA Library Prep Kit (Illumina, RS-20020595) and paired-end sequencing 178 was done with a NovaSeq 6000 instrument (Illumina) yielding 200-350 million reads per 179 sample. The raw data were subjected to QC analyses using the FastQC tool (version 180 0.11.9) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). mRNA-seq read 181 quality control was done using Trimmomatic²⁹ (version 0.36) and STAR RNA-seq³⁰ 182 (version STAR 2.5.4a) using 150 bp paired-end mode was used to align the reads (hg19). 183 HTSeq³¹ (version 0.9.1) was to retrieve the raw counts and subsequently, Bioconductor 184 package DESeq2³² in R (https://www.R-project.org/) was used to normalize the counts 185

7

across samples and perform differential expression gene analysis. Additionally, the 186 RUVSeq³³ package was applied to remove confounding factors. The data were pre-187 filtered keeping only genes with at least ten reads in total. The visualization was done 188 using dplyr (https://CRAN.R-project.org/package=dplyr) and ggplot2.³⁴ The genes with 189 log2 fold change >1 or <-1 and adjusted p-value (pAdj) <0.05 corrected for multiple testing 190 using the Benjamini-Hochberg method were considered significant and then conducted 191 gene enrichment analysis (GSEA, https://www.gsea-msigdb.org/gsea/msigdb). For T- or 192 B-cell receptor repertoire sequencing analysis, trimmed fastg files from bulk RNA-seq 193 were aligned against human V, D and J gene sequences using the default settings with 194 MiXCR.^{35,36} CDR3 sequence and the rearranged BCR/TCR genes were identified. 195

196

197 Statistical analysis

Differential expression gene (DEG) identification used Bioconductor package DESeq2 in R. P-values were calculated using a paired, two-side Wilcoxon test and adjusted p-value (pAdj) corrected using the Benjamini–Hochberg method. Genes with log2 fold change >1 or <-1, pAdj <0.05 and without 0 value from all sample were considered significant. For significance of each GSEA category, significantly regulated gene sets were evaluated with the Kolmogorov-Smirnov statistic. A value of **p* < 0.05, ***p* < 0.01, ****p* < 0.001, *****p* < 0.0001 was considered statistically significant.

205

206 Data Sharing Statement

The RNA-seq data from this study were deposited under the accession GSE201642 in the Gene Expression Omnibus (GEO). RNA-seq data of healthy heterologous vaccinated individuals were obtained under GSE201535.

210

211 Results

212 Patient characteristics

213 Patient characteristics are shown in Table 1, Figure 1A and Supplementary Table 1. At

the time of the vaccination, two patients (13%) had treatment-naïve CLL. Seven (47%)

- were on treatment without remission (2 frontline, 4 relapse) or with remission (1 relapse).
- Six (40%) were off therapy, including four in clinical complete or partial remission (2

8

frontline, 2 relapse) and two on relapse in need of treatment (1 frontline, 1 relapse). Of 217 the treated patients, four received venetoclax monotherapy and three ibrutinib 218 monotherapy. Eleven of 15 patients were previously on anti-CD20 monoclonal antibodies 219 with/without chemotherapy, either more than 12 months (7 patients) or within 12 months 220 (4 patients) prior to vaccination. Unfavorable prognostic CLL parameters included $\beta 2M$ 221 >3.5 mg/l (2/15), complex karyotype (2/15), trisomy 12 (1/15), unmutated IGHV gene 222 status (13/15), presence of TP53/del(17p) and/or del(11q) (6/15). Median IgG level was 223 224 619 mg/dl (range 159-1141), IgM level of 45 mg/dl (range <5-179) and IgA level of 98 mg/dl (range 12-210). Median ALC (absolute lymphocyte count) was 5.9/µl (range 3.3-225 46.7). 226

227

228 Antibody response

229 We analyzed anti-spike IgG antibody levels, neutralizing antibody levels and immune transcriptomes (RNA-seq) on peripheral immune cells prior to the vaccination (referred to 230 as Day (D) 0 (D0), on days 2 (D2), 7 (D7) and 14 (D14) and weeks 4-5 (W4-5) post 231 vaccination (Figure 1B). Circulating antibody levels were most closely correlated with 232 treatment history.^{9,37} After 2-dose vaccination, anti-spike (S) IgG was detected in 6/15 233 (40%) patients, including 2/6 (33%) off-therapy (#210, 212); 2/2 (100%) treatment-naïve 234 (#211, 213); 1/4 (25%) on active venetoclax (#203); 0/3 (0%) on ibrutinib; 1/4 (25%) on 235 anti-CD20 of less than 12 months (#209) (Figures. 2A and 3A; Supplementary Table 2). 236 Following three vaccination doses. 8/15 patients (53%) showed detectable anti-S 237 antibodies (Figures 2A and 3A; Supplementary Table 2). Several interesting responses 238 occurred after a three-dose heterologous regimen. Two naïve patients (#203, #209) that 239 received frontline therapy with acalabrutinib shortly before or after their third BNT162b2 240 dose retained seroconversion beyond 6 months post treatment. Patient #203 received 241 frontline treatment with venetoclax monotherapy prior to first ChAdOx1 vaccination, 242 showed a detectable anti-S IgG response at D14 post second ChAdOx1 dose that was 243 244 lost at W4-5 but then restored after a third BNT162b2 dose. Patient #209, who had an undiagnosed COVID-19 infection prior to receiving first vaccination and stopped 245 venetoclax+anti-CD20 treatment shortly before the second vaccination, showed an 246 247 antibody response after first vaccination and retained detectable antibody levels through

9

subsequential vaccination even with ongoing B-cell depletion in the context of CLL 248 remission. It is reported that SARS-CoV-2 infection leads to more robust and durable B 249 and T cell immune responses than COVID-19 vaccination in CLL patients.³⁸ Two patients 250 on ibrutinib (#107, 205), who failed humoral response after two homologous ChAdOx1 251 doses, seroconverted after the third heterologous BNT162b2 dose. Patient #107, who 252 was in second relapse and on ibrutinib treatment for two years, showed a delayed 253 seroconversion three months after a temporal pause of ibrutinib, while receiving a third 254 heterologous BNT162b2 dose. Patient #205, who was on ibrutinib within 6 months, 255 showed a delayed antibody response to the third heterologous BNT162b2 vaccination. 256 Results were consistent with the notion that patients with adequate levels of serum 257 immunoglobulins showed an increased antibody response after third vaccination, 258 259 whereas those with very low serum levels of IqA, IqG and IqM, respectively, failed to seroconvert following vaccination (Supplementary Table 1). Overall, 7/15 of patients 260 261 failed to mount a detectable humoral response even after 3-dose vaccination, irrespective of homologous or heterologous vaccination protocol. These patients were all heavily pre-262 263 treated. Three were on current venetoclax treatment (#103, 104, 201), one presented with CLL relapse with therapy pending (#106), one on prolonged ibrutinib (#208), and two with 264 265 anti-CD20 exposure less than 12 months before vaccination (#105, 206). Development of neutralizing antibodies was limited to the four patients showing a maximal antibody 266 267 response following 2-dose vaccination that was not boosted by 3-dose vaccination (# 210, 211, 212, 213) (Figure 2B; Supplementary Table 2). 268

269

270 Cellular immune response

271 Robust T cell responses were detected in 12/15 patients (80%) after 2-dose vaccination 272 and 14/15 patients (90%) following 3-dose vaccination (Figure 2C; Supplementary Table 3). T-cell response rate was independent of clinical characteristics, intrinsic immune and 273 treatment status (Figure 3B). All seropositive patients (8/8) as well as 6/7 seronegative 274 patients developed a T cell mediated IFN- γ response. The one seronegative patient 275 276 (#104) without a T cell response even after a third heterologous vaccination was on current venetoclax treatment. One patient (#213), who started frontline therapy with 277 acalabrutinib shortly before the third heterologous vaccination, lost T cell response. 278

10

Further analysis of cellular immune cell activation in all patients via flow cytometry
 revealed highly variable levels of activated and exhausted T cells, myeloid derived suppressor cells (MDSCs), and NK cells was performed but there was no correlation
 between these results and response rates detected by IFN-γ (Supplementary Table 4).

283

284 Transcriptional immune response

Next, we assessed the vaccine-induced innate immune response and transcriptional 285 286 response in PBMCs isolated from 2- and 3-dose vaccination cohorts at days 0 (D0), 2 287 (D2), 7 (D7) and week 4-5 (W4-5) following vaccination (Figure 1B). The sequencing depth of 200 million reads per sample permitted an in-depth analysis of early response 288 immunes and germline alleles induced by the vaccine. Reference cohorts were healthy 289 individuals receiving heterologous or homologous vaccinations.¹⁷ Samples were available 290 291 for eight patients: 3-dose BNT-BNT-ChAd (#103, #104, #106), 2-dose ChAd-ChAd (#201, #208, #209), 2-dose ChAd-BNT (#206, #212). First, numbers of differentially expressed 292 genes (DEGs) were measured to examine the immediate response upon vaccination 293 (Figure 4; Supplementary Figures 1-2). IFN- γ enrichment scores for DEGs at D2 were 294 independent of antibody response. High levels were found both in patients with (#209, 295 296 #212) and without (#201, #208) an antibody response (Figure 4A). Cell cycle pathway enrichment scores for DEGs were highest at D7, significantly higher both as compared to 297 D2 (Figure 4B) and D0 (Figure 4C). Similarly, higher enrichment in cell cycle pathways 298 also did not correlate with seroconversion (#106, #201, #208). Patient #104, the one 299 patient without a T-cell response, showed relatively low enrichment for both IFN-y 300 enrichment scores at D2 and cell cycle pathway enrichment at D7. Patient #206 had a 301 302 higher IFN- γ score at D7 compared to D2, suggesting delayed immune response. This patient exhibited a T-cell response and experienced a mild COVID-19 infection during 303 follow-up, but this was not associated with seroconversion. While the magnitude of 304 activation varied, activation of interferon-induced genes (IFI27, ISG15, CXCL10, GBP1), 305 JAK/STAT signaling genes including STAT1, antiviral pattern recognition receptors 306 (DDX58, DHX58) and OAS family genes at D2 were qualitatively similar to healthy 307 controls (Fig. 4D). Induction of *IFI6* and *IFIT* genes were higher in CLL patients compared 308 to healthy controls. While the transcriptome response varied greatly between individual 309

11

CLL patients and was independent of the clinical characteristics and treatment status, the
 vast majority of CLL patients regardless of antibody response exhibited an early
 transcriptome immune response presaging a later sustained T-cell mediated IFN-γ
 immune response.

314

315 Immunoglobulin germline repertoire

Finally, expression profiles of specific germline variable gene classes were interrogated. 316 317 First, the range of immunoglobulin heavy chain variable (IGHV), light chain (IGKV, IGLV), 318 and T cell receptor alpha/beta variable (TRAV, TRBV) gene usage in the CLL patients was assessed (Figures 5-6). Final clonotype numbers were more than four-fold lower at 319 D0 and D7 as compared to vaccinated healthy controls (Figure 5A). A broad range of 320 germlines in each patient was revealed by a deeper analysis of IGHV using 321 complementarity determining regions (CDR)1 and CDR2 (Figure 5B). We observed 322 IGHV3-74, IGHV3-30/IGHV3-33, IGHV1-18, IGHV3-23, IGHV3-21 and IGHV4-59 that are 323 the basis of neutralizing antibodies identified in SARS-CoV-2 patients.³⁹⁻⁴² In six patients 324 these clones were specifically increased (#103, #104, #201, #203, #212, #213). Three 325 antibody responsive patients, including treatment-naïve (#213), on venetoclax (#203), 326 and off-therapy (#212), showed relatively higher numbers of IGHV clones. Because of 327 transiently diminished B-cells upon active venetoclax treatment, patient #203 had more 328 IGHV clones at D0 and D7 than W4-5 while other antibody responsive patients (#209, 329 #210, #211) showed low and progressive numbers by recovered B cells. Notably, no B 330 cell receptor (BCR) clones were detected in the antibody non-responder #206, likely due 331 332 to completely depleted B cells by CLL treatment. Overall, results illustrate initially low levels of BCR in CLL patients lacking a humoral and neutralizing antibody response 333 gradually increase upon B-cell reconstitution with effective CLL therapy. In contrast to 334 BCR genes, activation of T Cell Receptor (TCR) genes (TRAV, TRBV) was readily 335 detected (Figure 6A), consistent with preservation of T cell responses. Several TRAV and 336 TRBV genes that are present in COVID-19 convalescent patients^{43,44} were induced in the 337 CLL patients at between D0 and W4-5 (Figure 6B). 338

339

340 **Discussion**

12

In this study, we demonstrate that CLL patients under active surveillance and those that 341 are treatment-naïve exhibit a superior response to COVID-19 vaccination than patients 342 on active treatment. While naïve or minimally treated patients showed an expanded 343 humoral and cellular immune response, the heavily pretreated patients exhibited only T 344 cell immune responses, even with repeated immune stimulation utilizing a heterologous 345 vaccination regimen. The value of a third vaccination was most pronounced in patients 346 who exhibited evidence of a recuperated immune system following effective CLL 347 treatment. These results coincided with pattern of transcriptional expression of immune 348 genes and BCR/TCR repertoire. 349

Interrogation of the transcriptional response to vaccination utilizing RNA-seq highlighted that nearly all CLL patients demonstrated transcriptional activation of early innate immune response pathways, including interferon-JAK/STAT signaling,^{17,25} within two days, regardless of the antibody response. Interferon-mediated innate immune response serves as a biomarker and plays a critical role in the immune system to control viral replication combating SARS-CoV-2 infection.^{17,45,46}

356 Skewed IGHV usage, including the appearance of *IGHV1-69*, *IGHV 4-34*, and 357 *IGHV 3-21*, was observed in the *BCR* repertoire of the CLL patients. Diverse *IGHV* usage 358 occurs in COVID-19 patients and vaccinated individuals.^{17,25}. In addition, the final number 359 of clonotypic B cells detected was much lower in non-IgG responders and even in the 360 seropositive CLL-patients were lower vaccinated healthy controls. The data is consistent 361 with increased numbers of SARS-CoV-2 specific IGHV clones correlating with an 362 improvement of humoral response rate and B-cell reconstitution.

Hypogammaglobulinemia in CLL patients results from leukemic cells perturbating 363 the interaction between T and B cells. Patients with low serum immunoglobulin levels 364 typically show ineffective humoral responses after both primary and subsequent boosting 365 doses.^{14,23,47} Half of patients with persistent immunodeficiency or B-cell depletion 366 following initial vaccination remain seronegative after a booster dose.^{8,9,14,48} T cell 367 immunity is essential for viral recognition and clearance and cellular responses can 368 prevent initial infection and seroconversion.^{10,23,48} T cells are especially critical in immune 369 protection against SARS-CoV-2 in cancer patients, who undergo therapy with B cell 370 depleting agents, such as anti-CD20 antibody.^{49,50} Here we report that CLL patients with 371

13

diminished numbers of functional CD19+ B cells, a key player in humoral response
 against SARS-CoV-2 virus, developed robust T cell immune responses to COVID-19
 vaccination.

Importantly, we also found a BTKi or BCL2i treatment-dependent effect on the 375 immune response to COVID-19 vaccine boosters. Vaccine effectiveness is moderated by 376 the time between treatment completion and vaccination.^{8,51} Here, CLL patients treated for 377 more than five years failed to seroconvert, while patients pretreated with the BTK 378 inhibitors ibrutinib or acalabrutinib for two years or less seroconverted after 2-3 doses of 379 a COVID-19 vaccine. Prolonged BTKi treatment predisposes patients towards an 380 ineffective vaccine immune response because B-cell maturation relies on functional 381 BTK.⁵² Increased serum IgA levels in BTKi-treated CLL patients appears to improve 382 383 functional humoral immunity demonstrated by decreased infection susceptibility and hospitalization rates.^{2,52} 384

Protection from severe disease, hospitalization and death by COVID-19 vaccination results from the combination of humoral immunity with a durable cellular immune memory response. In immunocompromised patients the timing of initial and booster vaccination should be carefully considered in reference to the underlying disease status. Remission-inducing therapy resulting in improved immune status and B-cell reconstitution improves adaptive immunity.¹²

391

392 Limitations of the study

There are several limitations to this study. The study was conducted on volunteers from a specific geographical area, Munich (Germany), total numbers of CLL patients were limited, and samples were not available from all patients for all vaccination timepoints for the RNA-seq studies.

397

398 Acknowledgments

Our gratitude goes to the participants who contributed to this study to advance our understanding of COVID-19 vaccination. This work used the computational resources of the NIH HPC Biowulf cluster (<u>http://hpc.nih.gov</u>). RNA-sequencing was conducted in the NIH Intramural Sequencing Center, NISC (<u>https://www.nisc.nih.gov/contact.htm</u>).

14

This work was supported by the Intramural Research Program (IRP) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Bavarian State Ministry of Science and Art, Special Program for the Promotion of COVID-19 Research (AKZ H.40001.1.7, to MB).

407

408 Authorship

Contribution: H.K.L., M.A.H., P.A.F., C.M.W. and L.H. designed the research study;
H.K.L. performed RNA-seq and data analysis; M.A.H and T.T.P. selected the patients,
collected, and curated data; H.K.L, M.A.H., M.B., T.T.P., P.A.F., C.M.W. and L.H.
analyzed results; H.K.L. prepared figures; H.K.L. and T.T.P prepared table; M.A.H., M.B.,
T.T.P., J.W.H., K.M., S.Z., H.V.B., P.G., R.W., L.B. and L.P. prepared samples; H.K.L,
M.A.H., M.B., P.A.F., C.M.W and L.H. wrote manuscript. All authors read and approved
the final version.

417 Disclosure of Conflicts of Interest

418 M.A.H. received consultancy fees from AstraZeneca. C.M.W. received consultancy fees

- 419 from AstraZeneca and BioNTech. The remaining authors declare no conflicts of interests.
- 420

15

421 **References**

1. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with 422 CLL: a multicenter international experience. Blood. 2020;136(10):1134-1143. 423 Scarfo L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and 2. 424 mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the 425 European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354-426 2363. 427 Roeker LE, Eyre TA, Thompson MC, et al. COVID-19 in patients with CLL: 428 3. improved survival outcomes and update on management strategies. Blood. 429 2021;138(18):1768-1773. 430 4. Crassini KR, Zhang E, Balendran S, et al. Humoral immune failure defined by 431 432 immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. Br J 433 434 Haematol. 2018;181(1):97-101. Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency 5. 435 436 and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(1):99-104. 437 Forconi F, Moss P. Perturbation of the normal immune system in patients with 438 6. CLL. Blood. 2015;126(5):573-581. 439 440 7. Benjamini O, Rokach L, Itchaki G, et al. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. 441 Haematologica. 2022;107(3):625-634. 442 Morawska M. Reasons and consequences of COVID-19 vaccine failure in 8. 443 patients with chronic lymphocytic leukemia. Eur J Haematol. 2022;108(2):91-98. 444 Roeker LE, Knorr DA, Thompson MC, et al. COVID-19 vaccine efficacy in 445 9. patients with chronic lymphocytic leukemia. Leukemia. 2021;35(9):2703-2705. 446 Liebers N, Speer C, Benning L, et al. Humoral and cellular responses after 10. 447 COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 448 2022;139(1):142-147. 449 Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-11. 450 19 mRNA vaccines in hematologic malignancies patients. *medRxiv*. 2021. 451

16

452	12. Barriere J, Re D, Peyrade F, Carles M. Current perspectives for SARS-CoV-2		
453	vaccination efficacy improvement in patients with active treatment against cancer. Eur J		
454	Cancer. 2021;154:66-72.		
455	13. Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is		
456	significantly less effective in patients with hematologic malignancies. Am J Hematol.		
457	2021;96(10):1195-1203.		
458	14. Herishanu Y, Rahav G, Levi S, et al. Efficacy of a third BNT162b2 mRNA		
459	COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.		
460	Blood. 2022;139(5):678-685.		
461	15. Parry H, McIlroy G, Bruton R, et al. Antibody responses after first and second		
462	Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J.		
463	2021;11(7):136.		
464	16. Banki Z, Mateus J, Rossler A, et al. Heterologous ChAdOx1/BNT162b2		
465	vaccination induces stronger immune response than homologous ChAdOx1		
466	vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.		
467	EBioMedicine. 2022;80:104073.		
468	17. Lee HK, Go J, Sung H, et al. Heterologous ChAdOx1-BNT162b2 vaccination in		
469	Korean cohort induces robust immune and antibody responses that includes Omicron.		
470	<i>iScience</i> . 2022;25(6):104473.		
471	18. European Medicines Agency (<u>https://www.ema.europa.eu/en/news/ema-ecdc-</u>		
472	recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-		
473	approach-can-be)		
474	19. Azzolini E, Pozzi C, Germagnoli L, et al. mRNA COVID-19 vaccine booster		
475	fosters B- and T-cell responses in immunocompromised patients. Life Sci Alliance.		
476	2022;5(6).		
477	20. Zaleska J, Kwasnik P, Paziewska M, et al. Response to anti-SARS-CoV-2 mRN		
478	vaccines in multiple myeloma and chronic lymphocytic leukemia patients. Int J Cancer		
479	2022.		
480	21. Lyski ZL, Kim MS, Xthona Lee D, et al. Immunogenicity of Pfizer mRNA COVID		
481	19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with		

482 Chronic Lymphocytic Leukemia. Case Rep Hematol. 2022;2022:6831640.

17

483	22.	Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-
-----	-----	---

484 specific T cells associates with rapid viral clearance and mild disease in COVID-19
485 patients. *Cell Rep.* 2021;34(6):108728.

486 23. Marasco V, Carniti C, Guidetti A, et al. T-cell immune response after mRNA

487 SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in

patients with lymphoid malignancies. *Br J Haematol*. 2022;196(3):548-558.

489 24. Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular

immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med.* 2021;218(5).

491 25. Lee HK, Knabl L, Moliva JI, et al. mRNA vaccination in octogenarians 15 and 20

492 months after recovery from COVID-19 elicits robust immune and antibody responses

that include Omicron. *Cell Rep.* 2022;39(2):110680.

494 26. Garg I, Sheikh AB, Pal S, Shekhar R. Mix-and-Match COVID-19 Vaccinations
495 (Heterologous Boost): A Review. *Infect Dis Rep.* 2022;14(4):537-546.

496 27. Thomson T, Prendecki M, Gleeson S, et al. Immune responses following 3rd and
497 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant

recipients. *EClinicalMedicine*. 2022;53:101642.

499 28. Haselmann V, Ozcurumez MK, Klawonn F, et al. Results of the first pilot external

quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing. *Clin Chem*

501 *Lab Med.* 2020;58(12):2121-2130.

S02 29. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
sequence data. *Bioinformatics*. 2014;30(15):2114-2120.

30. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq
aligner. *Bioinformatics*. 2013;29(1):15-21.

31. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with highthroughput sequencing data. *Bioinformatics*. 2015;31(2):166-169.

508 32. Love MI, Huber W, Anders S. Moderated estimation of fold change and 509 dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.

33. Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using

factor analysis of control genes or samples. *Nat Biotechnol*. 2014;32(9):896-902.

512 34. Wickham H. Ggplot2 : elegant graphics for data analysis. New York: Springer;

513 2009.

- 514 35. Bolotin DA, Poslavsky S, Mitrophanov I, et al. MiXCR: software for
- comprehensive adaptive immunity profiling. *Nat Methods*. 2015;12(5):380-381.
- 516 36. Bolotin DA, Poslavsky S, Davydov AN, et al. Antigen receptor repertoire profiling
- 517 from RNA-seq data. *Nat Biotechnol*. 2017;35(10):908-911.
- 518 37. Diamantopoulos PT, Stafylidis C, Vlachopoulou D, et al. Safety and
- immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic
- 520 lymphocytic leukemia: a prospective study. *Ther Adv Hematol*.
- 521 2022;13:20406207221090150.
- 522 38. Blixt L, Bogdanovic G, Buggert M, et al. Covid-19 in patients with chronic
- 523 lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in
- 524 consecutive patients. *Leukemia*. 2022;36(2):476-481.
- 525 39. Xiang H, Zhao Y, Li X, et al. Landscapes and dynamic diversifications of B-cell 526 receptor repertoires in COVID-19 patients. *Hum Immunol*. 2022;83(2):119-129.
- 40. Andreano E, Paciello I, Piccini G, et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. *Nature*. 2021;600(7889):530-535.
- 41. Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the
 recovery stage by single-cell sequencing. *Cell Discov.* 2020;6:31.
- 42. He B, Liu S, Wang Y, et al. Rapid isolation and immune profiling of SARS-CoV-2
- specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. *Signal Transduct Target Ther.* 2021;6(1):195.
- 43. Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological
- responses in patients with COVID-19. *Nat Immunol*. 2020;21(9):1107-1118.
- 536 44. Luo L, Liang W, Pang J, et al. Dynamics of TCR repertoire and T cell function in
- 537 COVID-19 convalescent individuals. *Cell Discov*. 2021;7(1):89.
- 538 45. Huang L, Shi Y, Gong B, et al. Dynamic blood single-cell immune responses in 539 patients with COVID-19. *Signal Transduct Target Ther*. 2021;6(1):110.
- 540 46. Knabl L, Lee HK, Wieser M, et al. BNT162b2 vaccination enhances interferon-
- 541 JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-
- 542 CoV-2 Beta variant. *Commun Med (Lond)*. 2022;2(1).

19

- 47. Lyski ZL, Kim MS, Xthona Lee D, et al. Cellular and humoral immune response
- to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. *Blood Adv.* 2022;6(4):1207-1211.
- 546 48. Re D, Seitz-Polski B, Brglez V, et al. Humoral and cellular responses after a third
- dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. *Nat*
- 548 *Commun*. 2022;13(1):864.
- 49. Riise J, Meyer S, Blaas I, et al. Rituximab-treated patients with lymphoma
- develop strong CD8 T-cell responses following COVID-19 vaccination. *Br J Haematol*.
- 551 2022;197(6):697-708.
- 552 50. Blixt L, Wullimann D, Aleman S, et al. T-cell immune responses following
- vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic
- 554 lymphocytic leukemia: results from a prospective open-label clinical trial.
- 555 *Haematologica*. 2022;107(4):1000-1003.
- 556 51. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19
- vaccine in patients with chronic lymphocytic leukemia. *Blood*. 2021;137(23):3165-3173.
- 558 52. Palma M, Mulder TA, Osterborg A. BTK Inhibitors in Chronic Lymphocytic
- Leukemia: Biological Activity and Immune Effects. *Front Immunol*. 2021;12:686768.
- 560

Table 1. Characteristics of CLL study population.

Ν	15
Age (years), median (range)	69 (59-82)
Gender	
Female	6 (40%)
Male	9 (60%)
Race	
Caucasian	15 (100%)
COVID-19 vaccination	
BNT-BNT-ChAd	4 (27%)
ChAd-BNT-BNT	2 (13%)
ChAd-ChAd-BNT	9 (60%)
Disease status	
Naive	2 (13%)
Frontline active	2 (13%)
Relapse active	3 (20%)
Relapse in need of treatment	2 (13%)
In remission	5 (33%)
Prior treatment (CT/CIT/IT)	
< 3	4 (27%)
≥ 3	7 (47%)
Current treatment	
BTK inhibitor	3 (20%)
Bcl2 inhibitor	4 (27%)
Off-therapy	6 (40%)
W&W	2 (13%)
IGHV status	
Mutated	2 (13%)
Risk factors	
Trisomy 12	1 (7%)
17p deletion/T53 mutation	5 (33%)
11q deletion	2 (13%)
Complex karyotype	2 (13%)
	2 (13%)
Serum IgG level (mg/dl), median (range)	619 (159-1141)
Serum IgM level (mg/dl), median (range)	45 (<5-179)
Serum IgA level (mg/dl), median (range)	98 (10-210)
B lymphocytes (%), median (range)	7.2 (0-84.6)

21



565

Figure 1. Study population and design. (A) CLL patient groups by treatment (naïve (n=2), treatment active (n=7), off-treatment (n=6)) and by drugs (BTKi (n=3), Bcl2i (n=4), anti-CD20 for less than 12 months (n=4), anti-CD20 for more than 12 months (n=2)). Mean distances between dose 1 and 2, and dose 2 and 3 were 82 and 132 days, respectively. (B) Blood samples were collected prior to the vaccination (D0) and at days 2 (D2), 7 (D7) and 14 (D14) and weeks 4-5 (W4-5) post second and third vaccination as indicated by the colored circles.

medRxiv preprint doi: https://doi.org/10.1101/2022.09.21.22280205; this version posted September 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.



Figure 2. Humoral and T cell immune responses following second dose and
booster vaccination. (A) Plasma IgG antibody binding against the S1 domain of SARSCoV-2 spike in CLL patients. (B) Neutralizing antibody response to SARS-CoV-2 RBD
(spike). (C) IFN-γ levels secreted from lymphocytes by stimulation of a SARS-CoV-2
peptide cocktail.



Figure 3. Anti-spike mediated T cell response in CLL patients. (A) Seroconversion
rate. (B) T cell response rate after 2-dose and 3-dose vaccines in patient subgroups
based on clinical parameters and treatment status. Y-axis presents the proportions (%) of
CLL patients. S, standard of active level, IgG: 552 mg/dl, IgM: 33 mg/dl, IgA: 69 mg/dl.





Figure 4. Immune transcriptomes following vaccination. (A-C) Interferon-regulated 587 genes are induced upon vaccination. Genes expressed at significantly higher levels at 588 days 2 and 7, as compared to day 0 were significantly enriched in Hallmark gene sets. X-589 axis denotes statistical significance as measured by minus logarithm of FDR q-values. Y-590 axis denotes ranked terms by q-values. (D) Heatmaps show log2 FC of IFN- γ response 591 genes (top) and G2M target genes (bottom) significantly regulated between day0 and 592 day2, day2 and day7, and day0 and day7. 593



594

Figure 5. SARS-CoV-2 B-cell memory. (A) Bar graphs were shown the number of clonotypes in each patient after the vaccination. (B) Pie charts for IGHV show the distribution of antibody sequences of individuals prior to the vaccination and after 7 days and 4~5 weeks. The number of sequences analyzed for individual are shown in the inner circle. Sizes of pie slices are proportional to the number of clonally related sequences. Persisting clones (same IGV genes) in both time points are shown as colored slices. White indicates sequences not overlapped between individuals.

26



602

Figure 6. SARS-CoV-2 T-cell memory. (A) Bar graphs were shown the number of clonotypes in each patient after the vaccination. (B) Box plots show the induction fold of variable (V) gene usage from TCR α and TCR β chain.